Access to Tirzepatide (Mounjaro®) for Weight Management in the Black Country
New community-based weight management services are being developed across the Black Country to support safe and effective access to tirzepatide (Mounjaro®), a medication that can help with weight loss and related health conditions. We anticipate these will be available via primary care from September 2025.
As part of our phased approach, the first group of patients who may be eligible will include those who:
- Have a BMI of 40 or more (or 37.5 for people from minority ethnic backgrounds),
- And have obstructive sleep apnoea on CPAP (or where CPAP is not tolerated)
And have at least three of the following long-term conditions:
- Type 2 diabetes
- High blood pressure (hypertension)
- Cardiovascular disease
- Dyslipidaemia
Other patients who meet the broader NHS criteria (BMI ≥ 40 and four or more related health conditions) may become eligible in later stages.
Please do not contact the practice about tirzepatide at this time. If you are eligible, you will be contacted by your practice.
Access to tirzepatide will be alongside structured diet, exercise and behavioural support to ensure patients are supported in achieving and maintaining a healthy weight.
Thank you for your patience as we work to introduce this important new treatment safely and fairly.
Please note:
Black Country ICB supports a practice’s decision to continue prescribing for a medicine that was initiated prior to the publication of the NICE Technology Appraisal (TA1026) 23rd December 2024, provided it meets the usual prescribing criteria requirements.
Tirzepatide for the management of type 2 diabetes is not part of this weight management pathway and is already prescribable as per Black Country ICB formulary website.
The ICB website has the latest ICB policy and FAQs for weight management published by NHS England, which may give you more information.
